%0 Journal Article
%T Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
%A Kiyoshi Komuta
%A Seigo Minami
%A Shouichi Ihara
%J Archive of "World Journal of Oncology".
%D 2019
%R 10.14740/wjon1184
%X The Gustave Roussy Immune Score (GRIm-Score) was developed based on the Royal Marsden Hospital (RMH) prognostic score for the purpose of a better patient selection for immunotherapy phase I trials. This scoring system is simply calculated by neutrophil-to-lymphocyte ratio, lactate dehydrogenase (LDH), and serum albumin concentration. The aim of our study was to determine whether GRIm-Score is a practically useful prognostic biomarker for advanced non-small cell lung cancer (NSCLC) patients treated with cytotoxic chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
%K Gustave Roussy Immune Score
%K Non-small cell lung cancer
%K Adenocarcinoma
%K Squamous cell carcinoma
%K Neutrophil-to-lymphocyte ratio
%K Serum albumin
%K Lactate dehydrogenase
%K Epidermal growth factor receptor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396777/